{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:56Z","timestamp":1790710136610,"version":"4.1.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T00:00:00Z","timestamp":1253664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T00:00:00Z","timestamp":1253664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s12028-009-9274-0","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T21:47:26Z","timestamp":1253656046000},"page":"132-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Immunomodulatory Therapies in Neurologic Critical Care"],"prefix":"10.1007","volume":"12","author":[{"given":"Logan M.","family":"McDaneld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis N.","family":"Bourdette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,23]]},"reference":[{"key":"9274_CR1","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1097\/01.ccm.0000281449.07719.2b","volume":"35","author":"G Broessner","year":"2007","unstructured":"Broessner G, Helbok R, Lackner P, et al. Survival and long-term functional outcome in 1,155 consecutive neurocritical care patients. Crit Care Med. 2007;35:2025\u201330.","journal-title":"Crit Care Med"},{"key":"9274_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/01.CCM.0000166389.85273.38","volume":"33","author":"JA Gomes","year":"2005","unstructured":"Gomes JA, Stevens RD, Lewin JJ III, Mirski MA, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit Care Med. 2005;33:1214\u201324.","journal-title":"Crit Care Med"},{"key":"9274_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0961203307079502","volume":"16","author":"BJ Parker","year":"2007","unstructured":"Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 2007;16:387\u201393.","journal-title":"Lupus"},{"key":"9274_CR4","unstructured":"Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;001331."},{"key":"9274_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97:370\u20133.","journal-title":"Acta Neurol Scand"},{"key":"9274_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archneur.63.7.930","volume":"63","author":"HC Lehmann","year":"2006","unstructured":"Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63:930\u20135.","journal-title":"Arch Neurol"},{"key":"9274_CR7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","volume":"23","author":"MH Mokrzycki","year":"1994","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23:817\u201327.","journal-title":"Am J Kidney Dis"},{"key":"9274_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2141.1978.tb01078.x","volume":"38","author":"AJ Keller","year":"1978","unstructured":"Keller AJ, Urbaniak SJ. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol. 1978;38:531\u201340.","journal-title":"Br J Haematol"},{"key":"9274_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1046\/j.1525-1594.2000.06521.x","volume":"24","author":"JH Yeh","year":"2000","unstructured":"Yeh JH, Chiu HC. Plasmapheresis-related hypotension. Artif Organs. 2000;24:705\u20139.","journal-title":"Artif Organs"},{"key":"9274_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ncpneuro0376","volume":"3","author":"R Gold","year":"2007","unstructured":"Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3:36\u201344.","journal-title":"Nat Clin Pract Neurol"},{"key":"9274_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","volume":"359","author":"SV Kaveri","year":"2008","unstructured":"Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med. 2008;359:307\u20139.","journal-title":"N Engl J Med"},{"key":"9274_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747\u201355.","journal-title":"N Engl J Med"},{"key":"9274_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","volume":"16","author":"D Paran","year":"2005","unstructured":"Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. [see comment]. Blood Coagul Fibrinol. 2005;16:313\u20138.","journal-title":"Blood Coagul Fibrinol"},{"key":"9274_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","volume":"38","author":"M Ballow","year":"2007","unstructured":"Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122\u201332.","journal-title":"Immunol Res"},{"key":"9274_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173\u201384.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9274_CR16","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain\u2013Barre syndrome [see comment]. Ann Neurol. 1990;27:S21\u20134.","journal-title":"Ann Neurol"},{"key":"9274_CR17","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1086\/513793","volume":"176","author":"RA Hughes","year":"1997","unstructured":"Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain\u2013Barre syndrome. J Infect Dis. 1997;176:S92\u20138.","journal-title":"J Infect Dis"},{"key":"9274_CR18","unstructured":"Bosch PE, Smith BE. Disorders of peripheral nerves. In: Neurology in clinical practice. 5th ed. Philadelphia: Butterworth-Heinemann; 2004. p. 2336\u20132345."},{"key":"9274_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/mus.880171004","volume":"17","author":"DW Zochodne","year":"1994","unstructured":"Zochodne DW. Autonomic involvement in Guillain\u2013Barre syndrome: a review. Muscle Nerve. 1994;17:1145\u201355.","journal-title":"Muscle Nerve"},{"key":"9274_CR20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.53.2.409","volume":"53","author":"RA Bernsen","year":"1999","unstructured":"Bernsen RA, de Jager AE, Schmitz PI, van der Meche FG. Residual physical outcome and daily living 3 to 6\u00a0years after Guillain\u2013Barre syndrome. Neurology. 1999;53:409\u201310.","journal-title":"Neurology"},{"key":"9274_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doorn","year":"2008","unstructured":"van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain\u2013Barre syndrome [see comment]. Lancet Neurol. 2008;7:939\u201350.","journal-title":"Lancet Neurol"},{"key":"9274_CR22","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591\u2013625.","journal-title":"Brain"},{"key":"9274_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1034\/j.1600-0404.2001.103005267.x","volume":"103","author":"D Chowdhury","year":"2001","unstructured":"Chowdhury D, Arora A. Axonal Guillain\u2013Barre syndrome: a critical review. Acta Neurol Scand. 2001;103:267\u201377.","journal-title":"Acta Neurol Scand"},{"key":"9274_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","volume":"39","author":"CE Hafer-Macko","year":"1996","unstructured":"Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625\u201335.","journal-title":"Ann Neurol"},{"key":"9274_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.410400414","volume":"40","author":"C Hafer-Macko","year":"1996","unstructured":"Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635\u201344.","journal-title":"Ann Neurol"},{"key":"9274_CR26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","volume":"35","author":"The Guillain\u2013Barre syndrome Study Group","year":"1985","unstructured":"The Guillain\u2013Barre syndrome Study Group. Plasmapheresis and acute Guillain\u2013Barre syndrome. Neurology. 1985;35:1096\u2013104.","journal-title":"Neurology"},{"key":"9274_CR27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","volume":"22","author":"French Cooperative Group on Plasma Exchange in Guillain\u2013Barre syndrome","year":"1987","unstructured":"French Cooperative Group on Plasma Exchange in Guillain\u2013Barre syndrome. Efficiency of plasma exchange in Guillain\u2013Barre syndrome: role of replacement fluids. Ann Neurol. 1987;22:753\u201361.","journal-title":"Ann Neurol"},{"key":"#cr-split#-9274_CR28.1","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2001;(2):CD001798","DOI":"10.1002\/14651858.CD001798"},{"key":"#cr-split#-9274_CR28.2","unstructured":"PMID: 11406009]. Cochrane Database Syst Rev. 2002;001798."},{"key":"9274_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Meche","year":"1992","unstructured":"van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barre syndrome. Dutch Guillain\u2013Barre Study Group. N Engl J Med. 1992;326:1123\u20139.","journal-title":"N Engl J Med"},{"key":"#cr-split#-9274_CR30.1","doi-asserted-by":"crossref","unstructured":"Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2004;(1):CD002063","DOI":"10.1002\/14651858.CD002063.pub2"},{"key":"#cr-split#-9274_CR30.2","unstructured":"PMID: 14973982]. Cochrane Database Syst Rev. 2006;002063."},{"key":"9274_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barre Syndrome Trial Group","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barre syndrome. Lancet. 1997;349:225\u201330.","journal-title":"Lancet"},{"key":"#cr-split#-9274_CR32.1","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barre syndrome [update of Cochrane Database Syst Rev. 2000;(3):CD001446","DOI":"10.1002\/14651858.CD001446"},{"key":"#cr-split#-9274_CR32.2","unstructured":"PMID: 10908498]. Cochrane Database Syst Rev. 2006;001446."},{"key":"9274_CR33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","volume":"61","author":"RA Hughes","year":"2003","unstructured":"Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain\u2013Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736\u201340.","journal-title":"Neurology"},{"key":"9274_CR34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1989.00520440064022","volume":"46","author":"RJ Barohn","year":"1989","unstructured":"Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878\u201384.","journal-title":"Arch Neurol"},{"key":"9274_CR35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/brain\/110.6.1617","volume":"110","author":"PA McCombe","year":"1987","unstructured":"McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987;110:1617\u201330.","journal-title":"Brain"},{"key":"9274_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/ana.410110205","volume":"11","author":"PJ Dyck","year":"1982","unstructured":"Dyck PJ, O\u2019Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136\u201341.","journal-title":"Ann Neurol"},{"key":"9274_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM198602203140801","volume":"314","author":"PJ Dyck","year":"1986","unstructured":"Dyck PJ, Daube J, O\u2019Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461\u20135.","journal-title":"N Engl J Med"},{"key":"9274_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055\u201366.","journal-title":"Brain"},{"key":"#cr-split#-9274_CR39.1","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2002;(2):CD001797"},{"key":"#cr-split#-9274_CR39.2","unstructured":"PMID: 12076423]. Cochrane Database Syst Rev. 2009;001797."},{"key":"9274_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838\u201345.","journal-title":"Ann Neurol"},{"key":"#cr-split#-9274_CR41.1","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2003;(1):CD003280","DOI":"10.1002\/14651858.CD003280"},{"key":"#cr-split#-9274_CR41.2","unstructured":"PMID: 12535467]. Cochrane Database Syst Rev. 2004;003280."},{"key":"9274_CR42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","volume":"31","author":"JJ Kelly Jr","year":"1981","unstructured":"Kelly JJ Jr, Kyle RA, O\u2019Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981;31:1480\u20133.","journal-title":"Neurology"},{"key":"#cr-split#-9274_CR43.1","doi-asserted-by":"crossref","unstructured":"Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies [update of Cochrane Database Syst Rev. 2003;(1):CD002827","DOI":"10.1002\/14651858.CD002827"},{"key":"#cr-split#-9274_CR43.2","unstructured":"PMID: 12535440]. Cochrane Database Syst Rev. 2006;002827."},{"key":"9274_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ana.21577","volume":"65","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286\u201393.","journal-title":"Ann Neurol"},{"key":"9274_CR45","doi-asserted-by":"crossref","unstructured":"Allen D, Lunn MP, Niermeijer J, Nobile-Orazio E. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev. 2007;005376.","DOI":"10.1002\/14651858.CD005376.pub2"},{"key":"9274_CR46","doi-asserted-by":"crossref","unstructured":"van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;004429.","DOI":"10.1002\/14651858.CD004429.pub2"},{"key":"#cr-split#-9274_CR47.1","doi-asserted-by":"crossref","unstructured":"Umapathi T, Hughes RA, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy [update of Cochrane Database Syst Rev. 2005;(3):CD003217","DOI":"10.1002\/14651858.CD003217.pub2"},{"key":"#cr-split#-9274_CR47.2","unstructured":"PMID: 16034892]. Cochrane Database Syst Rev. 2009;003217."},{"key":"9274_CR48","doi-asserted-by":"crossref","unstructured":"Vrancken AF, Hughes RA, Said G, Wokke JH, Notermans NC. Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev. 2007;006050.","DOI":"10.1002\/14651858.CD006050"},{"key":"9274_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11940-005-0022-2","volume":"7","author":"S Ahmed","year":"2005","unstructured":"Ahmed S, Kirmani JF, Janjua N, et al. An update on myasthenic crisis. Curr Treat Opt Neurol. 2005;7:129\u201341.","journal-title":"Curr Treat Opt Neurol"},{"key":"9274_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141\u20139.","journal-title":"Muscle Nerve"},{"key":"9274_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","volume":"23","author":"JM Lindstrom","year":"2000","unstructured":"Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453\u201377.","journal-title":"Muscle Nerve"},{"key":"9274_CR52","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357:2122\u20138.","journal-title":"Lancet"},{"key":"9274_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0165-5728(87)90092-0","volume":"15","author":"S Tzartos","year":"1987","unstructured":"Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 1987;15:185\u201394.","journal-title":"J Neuroimmunol"},{"key":"9274_CR54","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55:580\u20134.","journal-title":"Ann Neurol"},{"key":"9274_CR55","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","volume":"25","author":"J Berrouschot","year":"1997","unstructured":"Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis [see comment]. Crit Care Med. 1997;25:1228\u201335.","journal-title":"Crit Care Med"},{"key":"9274_CR56","doi-asserted-by":"crossref","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;002828.","DOI":"10.1002\/14651858.CD002828.pub2"},{"key":"9274_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mus.20075","volume":"30","author":"MB Bromberg","year":"2004","unstructured":"Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve. 2004;30:20\u201337.","journal-title":"Muscle Nerve"},{"key":"9274_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","volume":"261","author":"A Jani-Acsadi","year":"2007","unstructured":"Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261:127\u201333.","journal-title":"J Neurol Sci"},{"key":"9274_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00315690","volume":"238","author":"C Antozzi","year":"1991","unstructured":"Antozzi C, Gemma M, Regi B, et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. 1991;238:103\u20137.","journal-title":"J Neurol"},{"key":"9274_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1600-0404.1999.tb07336.x","volume":"99","author":"JH Yeh","year":"1999","unstructured":"Yeh JH, Chiu HC. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule. Acta Neurol Scand. 1999;99:147\u201351.","journal-title":"Acta Neurol Scand"},{"key":"9274_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/(SICI)1098-1101(2000)15:1\/2<74::AID-JCA6>3.0.CO;2-O","volume":"15","author":"R Weinstein","year":"2000","unstructured":"Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis. 2000;15:74\u2013128.","journal-title":"J Clin Apheresis"},{"key":"9274_CR62","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"DP Richman","year":"2003","unstructured":"Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis [see comment]. Neurology. 2003;61:1652\u201361.","journal-title":"Neurology"},{"key":"9274_CR63","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837\u201341.","journal-title":"Neurology"},{"key":"9274_CR64","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789\u201396.","journal-title":"Ann Neurol"},{"key":"#cr-split#-9274_CR65.1","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis [update in Cochrane Database Syst Rev. 2008;(1):CD002277","DOI":"10.1002\/14651858.CD002277.pub3"},{"key":"#cr-split#-9274_CR65.2","unstructured":"PMID: 18254004][update of Cochrane Database Syst Rev. 2003;(2):CD002277"},{"key":"#cr-split#-9274_CR65.3","unstructured":"PMID: 12804431]. Cochrane Database Syst Rev. 2006;002277."},{"key":"9274_CR66","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jnnp.57.5.578","volume":"57","author":"N Shibuya","year":"1994","unstructured":"Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994;57:578\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1191\/1352458502ms790oa","volume":"8","author":"HL Weiner","year":"2002","unstructured":"Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Multiple Sclerosis. 2002;8:142\u201354.","journal-title":"Multiple Sclerosis"},{"key":"9274_CR68","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1212\/01.wnl.0000259404.51352.7f","volume":"68","author":"S Tenembaum","year":"2007","unstructured":"Tenembaum S, Chitnis T, Ness J, Hahn JS, International Pediatric MS Study G. Acute disseminated encephalomyelitis. Neurology. 2007;68:S23\u201336.","journal-title":"Neurology"},{"key":"9274_CR69","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(09)70085-7","volume":"8","author":"PS Sorensen","year":"2009","unstructured":"Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009;8:519\u201329.","journal-title":"Lancet Neurol"},{"key":"9274_CR70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.56.10.1313","volume":"56","author":"S Schwarz","year":"2001","unstructured":"Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56:1313\u20138.","journal-title":"Neurology"},{"key":"9274_CR71","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"PS Sorensen","year":"2004","unstructured":"Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, TARIMS Study G. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63:2028\u201333.","journal-title":"Neurology"},{"key":"9274_CR72","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.59.8.1224","volume":"59","author":"S Tenembaum","year":"2002","unstructured":"Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002;59:1224\u201331.","journal-title":"Neurology"},{"key":"9274_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000008030","volume":"41","author":"P Jacquerye","year":"1999","unstructured":"Jacquerye P, Ossemann M, Laloux P, Dive A, De Coene B. Acute fulminant multiple sclerosis and plasma exchange. Eur Neurol. 1999;41:174\u20135.","journal-title":"Eur Neurol"},{"key":"9274_CR74","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/archneur.59.7.1074","volume":"59","author":"Y Mao-Draayer","year":"2002","unstructured":"Mao-Draayer Y, Braff S, Pendlebury W, Panitch H. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology. 2002;59:1074\u20137.","journal-title":"Neurology"},{"key":"9274_CR75","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1212\/WNL.43.6.1100","volume":"43","author":"M Rodriguez","year":"1993","unstructured":"Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993;43:1100\u20134.","journal-title":"Neurology"},{"key":"9274_CR76","first-page":"561","volume":"46","author":"R RamachandranNair","year":"2005","unstructured":"RamachandranNair R, Parameswaran M, Girija AS. Acute disseminated encephalomyelitis treated with plasmapheresis. Singapore Med J. 2005;46:561\u20133.","journal-title":"Singapore Med J"},{"key":"9274_CR77","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1212\/WNL.45.4.824","volume":"45","author":"DS Kanter","year":"1995","unstructured":"Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology. 1995;45:824\u20137.","journal-title":"Neurology"},{"key":"9274_CR78","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1537-2995.2007.01227.x","volume":"47","author":"LJ Ryan","year":"2007","unstructured":"Ryan LJ, Bowman R, Zantek ND, et al. Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Transfusion. 2007;47:981\u20136.","journal-title":"Transfusion"},{"key":"9274_CR79","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.39.9.1143","volume":"39","author":"HL Weiner","year":"1989","unstructured":"Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989;39:1143\u20139.","journal-title":"Neurology"},{"key":"9274_CR80","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878\u201386.","journal-title":"Ann Neurol"},{"key":"9274_CR81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M Keegan","year":"2002","unstructured":"Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58:143\u20136.","journal-title":"Neurology"},{"key":"9274_CR82","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0887-8994(99)00042-9","volume":"21","author":"M Nishikawa","year":"1999","unstructured":"Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol. 1999;21:583\u20136.","journal-title":"Pediatr Neurol"},{"key":"9274_CR83","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/088307389501000612","volume":"10","author":"M Kleiman","year":"1995","unstructured":"Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol. 1995;10:481\u20133.","journal-title":"J Child Neurol"},{"key":"9274_CR84","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-510X(99)00072-6","volume":"165","author":"S Pradhan","year":"1999","unstructured":"Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci. 1999;165:56\u201361.","journal-title":"J Neurol Sci"},{"key":"9274_CR85","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.46.4.1173","volume":"46","author":"JS Hahn","year":"1996","unstructured":"Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology. 1996;46:1173\u20134.","journal-title":"Neurology"},{"key":"9274_CR86","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","volume":"54","author":"DJ Sahlas","year":"2000","unstructured":"Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54:1370\u20132.","journal-title":"Neurology"},{"key":"9274_CR87","first-page":"258","volume":"21","author":"J Finsterer","year":"1998","unstructured":"Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol. 1998;21:258\u201361.","journal-title":"Clin Neuropharmacol"},{"key":"9274_CR88","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/jnnp.63.4.551","volume":"63","author":"R Markus","year":"1997","unstructured":"Markus R, Brew BJ, Turner J, Pell M. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry. 1997;63:551.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR89","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/PL00007836","volume":"249","author":"E Marchioni","year":"2002","unstructured":"Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol. 2002;249:100\u20134.","journal-title":"J Neurol"},{"key":"9274_CR90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1212\/01.wnl.0000318277.25679.9e","volume":"71","author":"DC Fu","year":"2008","unstructured":"Fu DC, Montgomery JR. High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology. 2008;71:294\u20135.","journal-title":"Neurology"},{"key":"9274_CR91","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jca.20103","volume":"21","author":"RP Lu","year":"2006","unstructured":"Lu RP, Keilson G. Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis. J Clin Apheresis. 2006;21:260\u20135.","journal-title":"J Clin Apheresis"},{"key":"9274_CR92","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/08830738020170111001","volume":"17","author":"E Shahar","year":"2002","unstructured":"Shahar E, Andraus J, Savitzki D, Pilar G, Zelnik N. Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol. 2002;17:810\u20134.","journal-title":"J Child Neurol"},{"key":"9274_CR93","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s00415-007-0561-4","volume":"254","author":"S Ravaglia","year":"2007","unstructured":"Ravaglia S, Piccolo G, Ceroni M, et al. Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol. 2007;254:1518\u201323.","journal-title":"J Neurol"},{"key":"9274_CR94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"LH Visser","year":"2004","unstructured":"Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Multiple Sclerosis. 2004;10:89\u201391.","journal-title":"Multiple Sclerosis"},{"key":"9274_CR95","first-page":"103","volume":"59","author":"Y Kanaheswari","year":"2004","unstructured":"Kanaheswari Y, Baizura J, Paeds M, Zulfiqar A. Intravenous immunoglobulin in the treatment of acute disseminated encephalomyelitis. Med J Malaysia. 2004;59:103\u20137.","journal-title":"Med J Malaysia"},{"key":"9274_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/1352458507082604","volume":"14","author":"V Kimiskidis","year":"2008","unstructured":"Kimiskidis V, Sakellari I, Tsimourtou V, et al. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Multiple Sclerosis. 2008;14:278\u201383.","journal-title":"Multiple Sclerosis"},{"key":"9274_CR97","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"HP Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018\u201325.","journal-title":"Lancet"},{"key":"9274_CR98","doi-asserted-by":"crossref","unstructured":"Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005;002127.","DOI":"10.1002\/14651858.CD002127.pub2"},{"key":"9274_CR99","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0022-510X(02)00335-0","volume":"206","author":"RE Gonsette","year":"2003","unstructured":"Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci. 2003;206:203\u20138.","journal-title":"J Neurol Sci"},{"key":"9274_CR100","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1474-4422(08)70020-6","volume":"7","author":"A Boster","year":"2008","unstructured":"Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, et al. Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008;7:173\u201383.","journal-title":"Lancet Neurol"},{"key":"9274_CR101","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJM198301273080401","volume":"308","author":"SL Hauser","year":"1983","unstructured":"Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173\u201380.","journal-title":"N Engl J Med"},{"key":"9274_CR102","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","volume":"54","author":"WH Likosky","year":"1991","unstructured":"Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. Journal of Neurol Neurosurg Psychiatry. 1991;54:1055\u201360.","journal-title":"Journal of Neurol Neurosurg Psychiatry"},{"key":"9274_CR103","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","volume":"337","author":"The Canadian Cooperative Multiple Sclerosis Study Group","year":"1991","unstructured":"The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet. 1991;337:441\u20136.","journal-title":"Lancet"},{"key":"9274_CR104","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00316148","volume":"214","author":"RE Gonsette","year":"1977","unstructured":"Gonsette RE, Demonty L, Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2\u20136\u00a0years. J Neurol. 1977;214:173\u201381.","journal-title":"J Neurol"},{"key":"9274_CR105","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/00127893-199705000-00005","volume":"3","author":"B Weinstock-Guttman","year":"1997","unstructured":"Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist. 1997;3:178\u201385.","journal-title":"Neurologist"},{"key":"9274_CR106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/135245850100700309","volume":"7","author":"OA Khan","year":"2001","unstructured":"Khan OA, Zvartau-Hind M, Caon C, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Multiple Sclerosis. 2001;7:185\u20138.","journal-title":"Multiple Sclerosis"},{"key":"9274_CR107","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/jnnp.71.3.404","volume":"71","author":"F Patti","year":"2001","unstructured":"Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71:404\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR108","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1001\/archneur.63.10.noc60076","volume":"63","author":"DE Gladstone","year":"2006","unstructured":"Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol. 2006;63:1388\u201393.","journal-title":"Arch Neurol"},{"key":"9274_CR109","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(04)00966-4","volume":"4","author":"Y Blanco","year":"2005","unstructured":"Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol. 2005;4:54\u201363.","journal-title":"Lancet Neurol"},{"key":"9274_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1023\/A:1006686426090","volume":"20","author":"A Fassas","year":"2000","unstructured":"Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis\u2014an interim analysis of efficacy. J Clin Immunol. 2000;20:24\u201330.","journal-title":"J Clin Immunol"},{"key":"9274_CR111","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s00415-002-0800-7","volume":"249","author":"A Fassas","year":"2002","unstructured":"Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, et al. Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002;249:1088\u201397.","journal-title":"J Neurol"},{"key":"9274_CR112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.62.2.282","volume":"62","author":"A Saiz","year":"2004","unstructured":"Saiz A, Blanco Y, Carreras E, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 2004;62:282\u20134.","journal-title":"Neurology"},{"key":"#cr-split#-9274_CR113.1","doi-asserted-by":"crossref","unstructured":"van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis [see comment] [update of Cochrane Database Syst Rev. 2003;(3):CD004405","DOI":"10.1002\/14651858.CD004405"},{"key":"#cr-split#-9274_CR113.2","unstructured":"PMID: 12918010]. Cochrane Database Syst Rev. 2007;004405."},{"key":"9274_CR114","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/00365540500276005","volume":"38","author":"M Ozen","year":"2006","unstructured":"Ozen M, Kanra G, Kara A, et al. Long-term beneficial effects of dexamethasone on intellectual and neuropsychological outcome of children with pneumococcal meningitis. Scand J Infect Dis. 2006;38:104\u20139.","journal-title":"Scand J Infect Dis"},{"key":"9274_CR115","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa065711","volume":"357","author":"M Scarborough","year":"2007","unstructured":"Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007;357:2441\u201350.","journal-title":"N Engl J Med"},{"key":"9274_CR116","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1086\/425368","volume":"39","author":"AR Tunkel","year":"2004","unstructured":"Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267\u201384.","journal-title":"Clin Infect Dis"},{"key":"9274_CR117","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa070852","volume":"357","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007;357:2431\u201340.","journal-title":"N Engl J Med"},{"key":"9274_CR118","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/jnnp.2004.049676","volume":"76","author":"S Kamei","year":"2005","unstructured":"Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76:1544\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR119","doi-asserted-by":"crossref","unstructured":"Martinez-Torres F, Menon S, Pritsch M, et al. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 2008;8:40.","DOI":"10.1186\/1471-2377-8-40"},{"key":"9274_CR120","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ana.21226","volume":"62","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;62:442\u201351.","journal-title":"Ann Neurol"},{"key":"9274_CR121","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/art.23300","volume":"58","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome. Arthritis Rheumatism. 2008;58:595\u2013603.","journal-title":"Arthritis Rheumatism"},{"key":"9274_CR122","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/MD.0b013e31818896e1","volume":"87","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Brown RD Jr, Calamia KT, et al. Angiography-negative primary central nervous system vasculitis: a syndrome involving small cerebral vessels. Medicine. 2008;87:264\u201371.","journal-title":"Medicine"},{"key":"9274_CR123","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.56.7.837","volume":"56","author":"S Lanthier","year":"2001","unstructured":"Lanthier S, Lortie A, Michaud J, Laxer R, Jay V, deVeber G. Isolated angiitis of the CNS in children. Neurology. 2001;56:837\u201342.","journal-title":"Neurology"},{"key":"9274_CR124","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/art.21766","volume":"54","author":"SM Benseler","year":"2006","unstructured":"Benseler SM, Silverman E, Aviv RI, et al. Primary central nervous system vasculitis in children. Arthritis Rheumatism. 2006;54:1291\u20137.","journal-title":"Arthritis Rheumatism"},{"key":"9274_CR125","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.21283","volume":"62","author":"LH Calabrese","year":"2007","unstructured":"Calabrese LH, Molloy ES, Singhal AB. Primary central nervous system vasculitis: progress and questions. Ann Neurol. 2007;62:430\u20132.","journal-title":"Ann Neurol"},{"key":"9274_CR126","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0002-9343(83)91125-7","volume":"74","author":"TR Cupps","year":"1983","unstructured":"Cupps TR, Moore PM, Fauci AS. Isolated angiitis of the central nervous system. Prospective diagnostic and therapeutic experience. Am J Med. 1983;74:97\u2013105.","journal-title":"Am J Med"},{"key":"9274_CR127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1212\/WNL.39.2.167","volume":"39","author":"PM Moore","year":"1989","unstructured":"Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology. 1989;39:167\u201373.","journal-title":"Neurology"},{"key":"9274_CR128","first-page":"2078","volume":"33","author":"KJ Bitter","year":"2006","unstructured":"Bitter KJ, Epstein LG, Melin-Aldana H, Curran JG, Miller ML. Cyclophosphamide treatment of primary angiitis of the central nervous system in children: report of 2 cases. J Rheumatol. 2006;33:2078\u201380.","journal-title":"J Rheumatol"},{"key":"9274_CR129","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2004.08.007","volume":"227","author":"M Volcy","year":"2004","unstructured":"Volcy M, Toro ME, Uribe CS, Toro G. Primary angiitis of the central nervous system: report of five biopsy-confirmed cases from Colombia. J Neurol Sci. 2004;227:85\u20139.","journal-title":"J Neurol Sci"},{"key":"9274_CR130","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s004150170154","volume":"248","author":"A Siva","year":"2001","unstructured":"Siva A. Vasculitis of the nervous system. J Neurol. 2001;248:451\u201368.","journal-title":"J Neurol"},{"key":"9274_CR131","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0749-0704(02)00027-1","volume":"18","author":"RA Hajj-Ali","year":"2002","unstructured":"Hajj-Ali RA, Ghamande S, Calabrese LH, Arroliga AC. Central nervous system vasculitis in the intensive care unit. Crit Care Clin. 2002;18:897\u2013914.","journal-title":"Crit Care Clin"},{"key":"9274_CR132","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jnnp.65.1.10","volume":"65","author":"PM Moore","year":"1998","unstructured":"Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry. 1998;65:10\u201322.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR133","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/art.23337","volume":"59","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Brown RD Jr, Calamia KT, et al. Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment. Arthritis Rheumatism. 2008;59:291\u20136.","journal-title":"Arthritis Rheumatism"},{"key":"9274_CR134","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543\u201354.","journal-title":"N Engl J Med"},{"key":"9274_CR135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25\u201336.","journal-title":"Ann Neurol"},{"key":"9274_CR136","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1215\/S1152851703000395","volume":"6","author":"S Vernino","year":"2004","unstructured":"Vernino S, O\u2019Neill BP, Marks RS, O\u2019Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncology. 2004;6:55\u201362.","journal-title":"Neuro-oncology"},{"key":"9274_CR137","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","volume":"60","author":"M Uchuya","year":"1996","unstructured":"Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR138","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/WNL.42.3.536","volume":"42","author":"F Graus","year":"1992","unstructured":"Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536\u201340.","journal-title":"Neurology"},{"key":"9274_CR139","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.38.9.1391","volume":"38","author":"NE Anderson","year":"1988","unstructured":"Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology. 1988;38:1391\u20138.","journal-title":"Neurology"},{"key":"9274_CR140","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","volume":"68","author":"F Keime-Guibert","year":"2000","unstructured":"Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR141","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2153::AID-CNCR16>3.0.CO;2-Y","volume":"78","author":"YB David","year":"1996","unstructured":"David YB, Warner E, Levitan M, Sutton DM, Malkin MG, Dalmau JO. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 1996;78:2153\u20136.","journal-title":"Cancer"},{"key":"9274_CR142","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/brain\/awh526","volume":"128","author":"BM Ances","year":"2005","unstructured":"Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764\u201377.","journal-title":"Brain"},{"key":"9274_CR143","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091\u20138.","journal-title":"Lancet Neurol"},{"key":"9274_CR144","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/brain\/awh077","volume":"127","author":"A Vincent","year":"2004","unstructured":"Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127:701\u201312.","journal-title":"Brain"},{"key":"9274_CR145","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ana.10713","volume":"54","author":"P Pozo-Rosich","year":"2003","unstructured":"Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol. 2003;54:530\u20133.","journal-title":"Ann Neurol"},{"key":"9274_CR146","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","volume":"62","author":"MJ Thieben","year":"2004","unstructured":"Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62:1177\u201382.","journal-title":"Neurology"},{"key":"9274_CR147","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.1097","volume":"50","author":"C Buckley","year":"2001","unstructured":"Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001;50:73\u20138.","journal-title":"Ann Neurol"},{"key":"9274_CR148","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/BF00900946","volume":"243","author":"I Kothbauer-Margreiter","year":"1996","unstructured":"Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996;243:585\u201393.","journal-title":"J Neurol"},{"key":"9274_CR149","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/archneur.63.2.197","volume":"63","author":"P Castillo","year":"2006","unstructured":"Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63:197\u2013202.","journal-title":"Arch Neurol"},{"key":"9274_CR150","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1440-1789.2004.00542.x","volume":"24","author":"KA Josephs","year":"2004","unstructured":"Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology. 2004;24:149\u201352.","journal-title":"Neuropathology"},{"key":"9274_CR151","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/archneur.63.2.175","volume":"63","author":"JY Chong","year":"2006","unstructured":"Chong JY, Rowland LP. What\u2019s in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis?[comment]. Arch Neurol. 2006;63:175\u20136.","journal-title":"Arch Neurol"},{"key":"9274_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jns.2004.08.015","volume":"228","author":"DJ Mahad","year":"2005","unstructured":"Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci. 2005;228:3\u20135.","journal-title":"J Neurol Sci"},{"key":"9274_CR153","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.yebeh.2005.11.005","volume":"8","author":"E Ferlazzo","year":"2006","unstructured":"Ferlazzo E, Raffaele M, Mazzu I, Pisani F. Recurrent status epilepticus as the main feature of Hashimoto\u2019s encephalopathy. Epilepsy Behav. 2006;8:328\u201330.","journal-title":"Epilepsy Behav"},{"key":"9274_CR154","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/01.nrl.0000259483.70041.55","volume":"13","author":"S Vernino","year":"2007","unstructured":"Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. Neurologist. 2007;13:140\u20137.","journal-title":"Neurologist"},{"key":"9274_CR155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/00007611-200093050-00014","volume":"93","author":"HC Chen","year":"2000","unstructured":"Chen HC, Marsharani U. Hashimoto\u2019s encephalopathy. South Med J. 2000;93:504\u20136.","journal-title":"South Med J"},{"key":"9274_CR156","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/WNL.53.7.1579","volume":"53","author":"RJ Caselli","year":"1999","unstructured":"Caselli RJ, Boeve BF, Scheithauer BW, O\u2019Duffy JD, Hunder GG. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology. 1999;53:1579\u201381.","journal-title":"Neurology"},{"key":"9274_CR157","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/WNL.41.2_Part_1.228","volume":"41","author":"PJ Shaw","year":"1991","unstructured":"Shaw PJ, Walls TJ, Newman PK, Cleland PG, Cartlidge NE. Hashimoto\u2019s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers\u2014report of 5 cases. Neurology. 1991;41:228\u201333.","journal-title":"Neurology"},{"key":"9274_CR158","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/archneur.60.2.164","volume":"60","author":"JY Chong","year":"2003","unstructured":"Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? [see comment]. Arch Neurol. 2003;60:164\u201371.","journal-title":"Arch Neurol"},{"key":"9274_CR159","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00023210-200721100-00002","volume":"21","author":"R Mocellin","year":"2007","unstructured":"Mocellin R, Walterfang M, Velakoulis D. Hashimoto\u2019s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21:799\u2013811.","journal-title":"CNS Drugs"},{"key":"9274_CR160","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/jnnp.2004.049395","volume":"76","author":"S Jacob","year":"2005","unstructured":"Jacob S, Rajabally YA. Hashimoto\u2019s encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry. 2005;76:455\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR161","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1052-3057(98)80038-4","volume":"7","author":"E Wirkowski","year":"1998","unstructured":"Wirkowski E, Libman RB, Batash M. Hashimot\u2019s encephalopathy\u2014response to intravenous immunoglobulin. J Stroke Cerebrovasc Dis. 1998;7:265\u20136.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9274_CR162","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp.70.1.132","volume":"70","author":"PM Boers","year":"2001","unstructured":"Boers PM, Colebatch JG. Hashimoto\u2019s encephalopathy responding to plasmapheresis. J Neurol Neurosurg Psychiatry. 2001;70:132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR163","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1212\/01.WNL.0000150733.84323.8F","volume":"64","author":"NS Hussain","year":"2005","unstructured":"Hussain NS, Rumbaugh J, Kerr D, Nath A, Hillis AE. Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy. Neurology. 2005;64:165\u20136.","journal-title":"Neurology"},{"key":"9274_CR164","first-page":"245","volume":"52","author":"T Nagpal","year":"2004","unstructured":"Nagpal T, Pande S. Hashimoto\u2019s encephalopathy: response to plasma exchange. Neurol India. 2004;52:245\u20137.","journal-title":"Neurol India"},{"key":"9274_CR165","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp.69.6.711","volume":"69","author":"J Palace","year":"2000","unstructured":"Palace J, Lang B. Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry. 2000;69:711\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9274_CR166","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1212\/01.wnl.0000187129.66353.13","volume":"65","author":"K McKnight","year":"2005","unstructured":"McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology. 2005;65:1730\u20136.","journal-title":"Neurology"},{"key":"9274_CR167","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.seizure.2005.07.002","volume":"14","author":"H Verhelst","year":"2005","unstructured":"Verhelst H, Boon P, Buyse G, et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure. 2005;14:412\u201321.","journal-title":"Seizure"},{"key":"9274_CR168","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0887-8994(02)00513-1","volume":"28","author":"DB Sinclair","year":"2003","unstructured":"Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol. 2003;28:194\u20138.","journal-title":"Pediatr Neurol"},{"key":"9274_CR169","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.seizure.2006.05.010","volume":"15","author":"A Okumura","year":"2006","unstructured":"Okumura A, Tsuji T, Kato T, Natsume J, Negoro T, Watanabe K. ACTH therapy for generalized seizures other than spasms. Seizure. 2006;15:469\u201375.","journal-title":"Seizure"},{"key":"9274_CR170","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1111\/j.1528-1157.1996.tb06026.x","volume":"37","author":"AN Prasad","year":"1996","unstructured":"Prasad AN, Stafstrom CF, Holmes GL. Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Epilepsia. 1996;37:S81\u201395.","journal-title":"Epilepsia"},{"key":"9274_CR171","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/brain\/awh415","volume":"128","author":"CG Bien","year":"2005","unstructured":"Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128:454\u201371.","journal-title":"Brain"},{"key":"9274_CR172","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1212\/WNL.46.1.242","volume":"46","author":"PI Andrews","year":"1996","unstructured":"Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen\u2019s encephalitis. Neurology. 1996;46:242\u20136.","journal-title":"Neurology"},{"key":"9274_CR173","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1212\/WNL.54.11.2163","volume":"54","author":"M Lousa","year":"2000","unstructured":"Lousa M, Sanchez-Alonso S, Rodriguez-Diaz R, Dalmau J. Status epilepticus with neuron-reactive serum antibodies: response to plasma exchange. Neurology. 2000;54:2163\u20135.","journal-title":"Neurology"},{"key":"9274_CR174","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/NRL.0b013e3181578952","volume":"14","author":"F Nahab","year":"2008","unstructured":"Nahab F, Heller A, Laroche SM. Focal cortical resection for complex partial status epilepticus due to a paraneoplastic encephalitis. Neurologist. 2008;14:56\u20139.","journal-title":"Neurologist"},{"key":"9274_CR175","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/01.ATV.0000121481.56512.c6","volume":"24","author":"L Mosca","year":"2004","unstructured":"Mosca L, Appel LJ, Benjamin EJ, et al. Summary of the American Heart Association\u2019s evidence-based guidelines for cardiovascular disease prevention in women. Arterioscl Thromb Vasc Biol. 2004;24:394\u20136.","journal-title":"Arterioscl Thromb Vasc Biol"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-009-9274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-009-9274-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-009-9274-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-009-9274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:00:25Z","timestamp":1744164025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-009-9274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,23]]},"references-count":185,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["9274"],"URL":"https:\/\/doi.org\/10.1007\/s12028-009-9274-0","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,23]]},"assertion":[{"value":"4 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}